Search for: "USPTO" Results 1521 - 1540 of 18,339
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Feb 2023, 9:36 am by Richard Marsolais
Here is a link to the USPTO website for additional information. [read post]
1 Feb 2023, 11:23 am by Eileen McDermott
Patent and Trademark Office (USPTO) Director David Kappos explained on a panel about potential reform of the Patent Trial and Appeal Board (PTAB) that the PTAB was meant to be an alternative to district court, but “that hasn’t worked out. [read post]
1 Feb 2023, 11:23 am by Eileen McDermott
Patent and Trademark Office (USPTO) Director David Kappos explained on a panel about potential reform of the Patent Trial and Appeal Board (PTAB) that the PTAB was meant to be an alternative to district court, but “that hasn’t worked out. [read post]
1 Feb 2023, 11:00 am by Dennis Crouch
Certificate of Cancellation: Once the appeal is complete, the USPTO Director then issues a certificate canceling the claim. 35 U.S.C. 316. [read post]
1 Feb 2023, 10:10 am by Jake Ward
Press release from USPTO today: Beware of spoofed calls that impersonate the USPTO Scammers have recently started calling trademark customers and falsely claiming to be an employee with the United States Patent and Trademark Office (USPTO). [read post]
1 Feb 2023, 8:11 am by centerforartlaw
By Murphy Yanbing Chen Introduction Traditional Knowledge (“TK”) and Traditional Cultural Expression (“TCE”) bear a record of the collective memories of indigenous people. [read post]
1 Feb 2023, 5:28 am by Russ Krajec
Last October, the United States Patent and Trademark Office (USPTO) issued a Request for Comments on USPTO Initiatives To Ensure the Robustness and Reliability of Patent Rights. [read post]
1 Feb 2023, 5:28 am by Russ Krajec
Last October, the United States Patent and Trademark Office (USPTO) issued a Request for Comments on USPTO Initiatives To Ensure the Robustness and Reliability of Patent Rights. [read post]
31 Jan 2023, 10:32 am by Alec Pronk
The United States Patent and Trademark Office (USPTO) yesterday announced a final rule to eliminate the provisions within the agency’s rules related to voluntary continuing legal education (CLE) certification and recognition for registered patent practitioners and individuals granted limited recognition to practice in patent matters before the USPTO. [read post]
31 Jan 2023, 10:32 am by Alec Pronk
The United States Patent and Trademark Office (USPTO) yesterday announced a final rule to eliminate the provisions within the agency’s rules related to voluntary continuing legal education (CLE) certification and recognition for registered patent practitioners and individuals granted limited recognition to practice in patent matters before the USPTO. [read post]
Amazon’s APEX program allows patent holders to have their patents examined by a neutral third-party patent examiner, rather than the United States Patent and Trademark Office (“USPTO”). [read post]
31 Jan 2023, 8:40 am by Jason Rantanen
Figure 6 In addition to providing a picture of what’s being filed at the Federal Circuit, the docket dataset also allows us to match up the Federal Circuit decisions to other datasets of district court and PTO data, such as the USPTO Patent Litigation dataset and the Stanford NPE Litigation Dataset. [read post]
31 Jan 2023, 7:20 am by Kluwer IP Reporter
Read the full story here USPTO launches trademark Virtual Assistant The United States Patent and Trademark Office (USPTO) has recently launched Virtual Assistant to provide immediate answers to general customer queries in a specific manner. [read post]
31 Jan 2023, 4:15 am by Pedram Sameni
According to the United States Patent and Trademark Office (USPTO), economic growth is driven by innovation and supported through intellectual property. [read post]
31 Jan 2023, 4:15 am by Pedram Sameni
According to the United States Patent and Trademark Office (USPTO), economic growth is driven by innovation and supported through intellectual property. [read post]
Thomas suggested that FDA “should read the claims of issued patents as the USPTO granted them, not in a summary” provided by brand-name drug companies, enlisting the USPTO’s expertise to do so, if necessary. [read post]